Magellan’s Haita Makanji, vice president, clinical specialty solutions, was featured in Managed Healthcare Executive this week, discussing some ground breaking new gene therapies that are available for hemophilia sufferers. These therapies promise the potential of fewer infusions and bleeding episodes.
You can read the complete article at Managed Healthcare Executive by clicking here.
